Information Provided By:
Fly News Breaks for May 17, 2016
ANAC, PFE
May 17, 2016 | 07:39 EDT
Leerink analyst Seamus Fernandez says Pfizer's (PFE) all-cash $5.2B deal to acquire Anacor (ANAC) came as a surprise to him. However, the deal is "intriguing" as it provides a "meaningful" additional revenue stream within the Innovative Business and leverages Pfizer's footprint in pediatrics and primary care, the analyst tells investors in a research note. Fernandez reiterates a Market Perform and $35.50 price target on Pfizer's shares.
News For PFE;ANAC From the Last 2 Days
PFE
Dec 11, 2018 | 11:20 EDT
Check out today's top analyst calls from around Wall Street, compiled by The Fly. CITI UPGRADES AT&T... To see the rest of the story go to thefly.com. See Story Here
PFE
Dec 11, 2018 | 10:33 EDT
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Overweight at JPMorgan with analyst Christopher Schott citing valuation. 2. Splunk (SPLK) resumed with a Neutral from Buy at Guggenheim with analyst Imtiaz Koujalgi saying while the company's fundamentals are strong, he's "looking for more clarity." 3. CalAmp (CAMP) downgraded to Outperform from Strong Buy at First Analysis and to Market Perform from Outperform at Northland. 4. Acorda Therapeutics (ACOR) downgraded to Sell from Neutral at Goldman Sachs with analyst Salveen Richter saying the commercial outlook for Inbrija appears limited. 5. Versum Materials (VSM) downgraded to Sell from Neutral at Goldman Sachs with analyst Toshiya Hari saying while he remains constructive on the Semiconductor Materials sub-sector broadly, he believes the market is underestimating the extent to which weaker semiconductor capital expenditures could negatively impact the Delivery Systems and Services segment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE
Dec 11, 2018 | 05:18 EDT
JPMorgan analyst Christopher Schott downgraded Pfizer to Neutral with an unchanged price target of $46. The shares closed yesterday up 48c to $44.40. The analyst cites valuation for his move to the sidelines after a "strong" 2018 which has to the stock up over 20% year-to-date. Further, he believes Pfizer's product pipeline needs to expand following the patent expiration of Lyrica in 2019.